Next Steps With CAR T-Cell Therapy in Multiple Myeloma: Omar Castaneda Puglianini, MD

Video

The hematologist and medical oncologist discussed next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Omar Castaneda Puglianini, MD, hematologist and medical oncologist, Moffitt Cancer Center, to learn more about next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

Idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel), the former FDA-approved and the latter an investigational CAR T-cell therapy, have both demonstrated efficacy in heavily pretreated multiple myeloma.

Puglianini discussed the importance of improving upon the duration of response (DOR) observed with these regimens. Moreover, novel strategies are being examined, as is the role of maintenance therapy patients who progress on CAR T-cell therapy in terms of prolonging DOR, Castaneda Puglianini notes.

Also, developments are being made regarding how to sequence therapies, such as bispecific antibodies or antibody-drug conjugates targeting antigens beyond BCMA, in the post–CAR T-cell therapy space, Castaneda Puglianini continues. These are all areas in need of further examination to improve patient responses, especially in individuals with penta-refractory or triple-class refractory disease who currently have poor overall survival, Castaneda Puglianini concludes.

Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
© 2024 MJH Life Sciences

All rights reserved.